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Background: Low drug entrapment efficiency of hydrophilic drugs into poly(lactic-co-glycolic 
acid) (PLGA) nanoparticles is a major drawback. The objective of this work was to investigate 
different methods of producing PLGA nanoparticles containing minocycline, a drug suitable 
for periodontal infections.
Methods: Different methods, such as single and double solvent evaporation emulsion, ion 
pairing, and nanoprecipitation were used to prepare both PLGA and PEGylated PLGA 
  nanoparticles. The resulting nanoparticles were analyzed for their morphology, particle size 
and size distribution, drug loading and entrapment efficiency, thermal properties, and   antibacterial 
activity.
Results: The nanoparticles prepared in this study were spherical, with an average particle size 
of 85–424 nm. The entrapment efficiency of the nanoparticles prepared using different methods 
was as follows: solid/oil/water ion pairing (29.9%) . oil/oil (5.5%) . water/oil/water 
(4.7%) . modified oil/water (4.1%) . nano precipitation (0.8%). Addition of dextran sulfate 
as an ion pairing agent, acting as an ionic spacer between PEGylated PLGA and minocycline, 
decreased the water solubility of minocycline, hence increasing the drug entrapment efficiency. 
Entrapment efficiency was also increased when low molecular weight PLGA and high molecular 
weight dextran sulfate was used. Drug release studies performed in phosphate buffer at 
pH 7.4 indicated slow release of minocycline from 3 days to several weeks. On antibacterial 
analysis, the minimum inhibitory concentration and minimum bactericidal concentration of 
nanoparticles was at least two times lower than that of the free drug.
Conclusion: Novel minocycline-PEGylated PLGA nanoparticles prepared by the ion pairing 
method had the best drug loading and entrapment efficiency compared with other prepared 
nanoparticles. They also showed higher in vitro antibacterial activity than the free drug.
Keywords: nanoparticle, PEGylation, PLGA, ion pairing, minocycline, antibacterial
Introduction
Many biodegradable polymers such as chitosan, gelatin, poly(lactic-co-glycolic acid) 
(PLGA), polymethylmethacrylate, polycaprolactone, and poly(lactic acid) are used 
for the preparation of microparticles and nanoparticles.1–5 PLGA is one of the most 
biocompatible and biodegradable polymers, and it has been widely studied for prepar-
ing drug-loaded nanoparticles.6,7 Several methods, such as phase separation or coacer-
vation, emulsification diffusion, spray-drying, and emulsion-solvent evaporation 
techniques have been used to prepare PLGA nanoparticles.8–11 Using emulsion solvent 
evaporation methods, various drug molecules have been encapsulated into PLGA 
nanoparticles.12,13 For preparation of nanoparticles, the choice of a particular method 
primarily depends on the hydrophilicity/hydrophobicity of the drug molecule and 
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stability considerations. The pattern of drug release from 
particles depends on some of their characteristics, including 
size, size distribution, entrapment efficiency, and drug 
lo  ading.14 These characteristics are influenced by some of 
the preparation parameters, such as power and duration of 
energy applied, organic and aqueous phase volume, polymer 
and drug concentration, polymer molecular weight, and 
solvent volume. Each of these parameters influences the size 
and/or the drug loading of the nanoparticles.
In the field of oral diseases, polymeric-based drug delivery 
systems, such as fibers, strips, or microparticles, have been 
used for local drug delivery in dentistry to provide adequate 
drug concentrations directly at the site of action. These systems 
are usually inserted into the periodontal pocket or injected in 
periodontal tissues to both enhance the therapeutic effects of 
drugs and reduce the side effects of drugs related to their sys-
temic use. Local delivery systems have been suggested as a 
novel concept for treatment of periodontal diseases, especially 
in cases that are recurrent and chronic. Several specialized local 
delivery systems have been designed for controlled release of 
antibiotics in periodontal tissues.15,16 The complexity of access 
to periodontal tissues makes all of these systems only partially 
successful.17 There are a few studies about preparation of 
antibacterial nanoparticles for periodontal therapy.18,19
Nanoparticles provide several advantages. For example, 
because of their small size, they penetrate areas (extracellular 
and intracellular areas) that may be inaccessible to other deliv-
ery systems, such as bacterial cells, alveolar bone trabeculae, 
and from the gingival sulcus inward to the underlying connec-
tive tissue and to the periodontal pocket areas below the gum 
line.17,19,20 Nanoparticles protect a drug against in vivo degrada-
tion and reduce side effects. They also have more favorable 
drug pharmacokinetics.21 Further, compared with microparti-
cles, nanoparticles have better stability in biological fluids.
Accordingly, nanoparticles can provide a potential peri-
odontal carrier system for the delivery of antibiotics to 
periodontal tissues. These systems reduce the dosage and 
frequency of antibiotic usage and further provide an adequate 
supply of antibiotics over an extended period of time. 
D  ifferent properties of nanoparticles, such as particle size, 
entrapment efficiency, minimum inhibitory concentration 
(MIC), minimum bactericidal concentrations (MBC), and 
drug release influence the clinical outcome of drug therapy 
via the following mechanisms:
•	 Smaller particle size facilitates the penetration of nano-
particles and enhances their antibacterial properties
•	 Higher entrapment efficiency of nanoparticles increases 
the drug content at the site of action
•	 Lower MIC and MBC achieved with nanoparticles 
  indicates that better antibacterial activity is achieved with 
a smaller amount of drug
•	 In periodontal treatment, a higher concentration of anti-
biotic at initial times and thereafter a constant release of 
antibiotic with lower concentration is required, which is 
achieved with nanoparticles.
Minocycline has a broader spectrum of activity than other 
members of the tetracycline group of antibiotics. It is a long-
acting and bacteriostatic antibiotic. Generally it has serum 
levels higher than those of simple tetracyclines because of 
its long half-life. Minocycline is used primarily to treat acne 
and other similar skin diseases, but in accordance with the 
broader spectrum of activity of minocycline, it also acts 
against periodontal pathogens. Minocycline-loaded micro-
capsules have been investigated in periodontal treatments.22–24 
It has been effectively used for treatment of periodontitis and 
related infections in periodontal diseases.25–27 The major 
advantage of minocycline is its anticollagenase properties 
and ability to reduce soft tissue destruction and bone resorp-
tion which is very important in the treatment of periodontal 
disease.19 In addition, minocycline is a good candidate for 
local antibiotic delivery.28,29 In this study, minocycline was 
chosen to be incorporated into PLGA nanoparticles. Due to 
the high hydrophilicity of minocycline and its rapid partition-
ing to the aqueous phase, preparation of minocycline PLGA 
nanoparticles remains a real challenge.
Development of new methods for the delivery of hydro-
philic drugs is emerging as an important research field in 
pharmaceutics.30,31 In contrast with lipophilic drugs, there 
are some problems with encapsulation of hydrophilic 
agents.32,33 The commonly utilized methods for preparing 
hydrophilic drugs in nanoparticles suffer from low drug 
loading because during preparation the drug rapidly diffuses 
to the external aqueous phase.34 However, another problem 
with hydrophilic drugs is that the drug particles usually 
encapsulated in the form of small clusters on the surface or 
within the polymer matrix just below the surface of the 
particles, resulting in a high initial burst release.35
In this study, we used several preparation strategies to 
improve the encapsulation efficiency and loading of mino-
cycline as a hydrophilic drug. Water/oil/water and solid/oil/
water emulsification were used for the hydrochloride salt 
form of minocycline. The oil/oil, oil/water emulsification, 
and nanoprecipitation methods were used for the non-salt 
form of minocycline. We made some modifications to the 
preparation methods, such as adding lecithin as an 
amphiphilic compound to the water phase and/or organic 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
222
Kashi et alInternational Journal of Nanomedicine 2012:7
phase, or using PEGylated PLGA.36 PEG can be used as a 
promising material in biomedical applications, because of 
its good hydrophilicity, low toxicity, excellent biocompatibil-
ity, and biodegradability.37 Both the solid/oil/water and ion 
pairing techniques were combined in one method to encap-
sulate hydrophilic drugs. We hypothesized that use of PEGy-
lated PLGA (with different molecular weights) as an 
amphiphilic copolymer and dextran sulfate (with different 
molecular weights) as an ion pairing agent could result in a 
better encapsulation yield of cationic molecules in 
nanoparticles. Dextran sulfate was used to reduce drug solu-
bility by coacervating molecules that diffuse slowly to the 
external phase and allow encapsulation of the coacervate on 
the polymeric precipitate. Dextran sulfate is a polyanionic 
derivative of dextran (a polymer of anhydroglucose) and has 
been utilized in various pharmaceutical formulations.38,39 
Finally, nanoparticles were characterized and compared for 
their size, morphology, and especially drug loading, drug 
entrapment efficiency, and in vitro drug release profile. In 
addition, the antibacterial effect of nanoparticles against 
standard Aggregatibacter actinomycetemcomitans, the most 
important pathogen in periodontal infections, was investi-
gated in vitro.40
Materials and methods
Materials
PLGA (Resomer 502H and 504H, with a lactic to glycolic 
acid ratio of 50:50) was purchased from Boehringer Ingelheim 
(Ingelheim, Germany). Polyvinyl alcohol (molecular weight 
30,000–70,000), dextran sulfate sodium salt (molecular 
weight 6000 and 500,000 Da), bifunctional NH2-PEG-NH2 
(molecular weight of 3350 Da), sorbitan monooleate 
(Span 80), N-hydroxy succinimide, and dicyclohexylcarbo-
diimide were purchased from Sigma-Aldrich (St Louis, MO). 
Lecithin and high pressure liquid ch  romatography (HPLC) 
grade dimethyl formamide and tetrahydrofuran were obtained 
from Merck (Darmstadt, Germany). Minocycline was pur-
chased from Kouting Chemical Co, Ltd, (Songjang, China). 
Deionized water was used throughout the experiment. Brain 
heart infusion agar (Merck) was used for microbiological 
tests. All other agents and solvents were analytical or reagent 
grade and used as received.
Nanoparticle preparation
O/W emulsion technique
Oil in water emulsification was performed according to the 
method developed by Esmaeili et al, with a little m  odification.41 
Drug and polymer solution were prepared by   dissolving 
150 mg minocycline and 350 mg of PLGA 504H in 20 mL 
of dichloromethane at room temperature using a magnetic 
stirrer (Heidolph, Germany). The organic phase was injected 
through a syringe equipped with a 20-G angiocatheter into 
75 mL of an aqueous polyvinyl alcohol solution and homog-
enized (Ultra-turrax, IKA, Germany) at 24,000 rpm for 
5 minutes. The emulsion was then sonicated (Misonix, USA) 
for 2 minutes (30 W). The resulting nanoemulsion was 
maintained under a mechanical stirrer (IKA) under gentle 
mixing for 4 hours to evaporate off the organic solvent. After 
evaporation, nanoparticles were collected by centrifugation 
(Sigma 3K30, Germany) at 20,000 rpm for 20 minutes and 
washed three times with deionized water to remove nonen-
capsulated drug and the remaining solvent. The nanoparticle 
dispersion was freeze-dried at −40°C for 48 hours (Christ, 
Alpha 2-4 LD, Germany) to obtain a fine powder.
Modified O/W emulsion technique
Phospholipid lecithin 20 mg was added to the water phase, 
oil phase, and oil and water phase as an amphiphilic com-
pound according to the method reported by Cheow and 
Hadinoto.36 The O/W process was carried out according to 
the previous section with 100 mg of minocycline and 400 mg 
of PLGA 504H.
O/O emulsion technique
Oil in oil emulsification was performed according to the method 
developed by Mahdavi et al, with a little   modification.42 Drug 
and polymer solution was prepared by dissolving 7.5 mg of 
minocycline and 37.5 mg PLGA 504H in 3 mL of acetonitrile. 
This solution was added into 40 mL of viscous liquid paraffin 
containing 200 µL Span 80 and continuously stirred, yielding 
a finely dispersed drug suspension. The suspension was heated 
to 55°C and stirred for 2 hours to ensure complete evaporation 
of acetonitrile. Nanoparticles were collected by centrifugation 
at 20,000 rpm for 20 minutes and washed three times with 
n-hexane to remove residual mineral oil and Span 80. The 
nanoparticle dispersion was then freeze-dried for 48 hours.
W/O/W emulsion technique
A double emulsion process was performed according to the 
method developed by Dillen et al, with a little modification.43 
An aqueous solution of minocycline was prepared by dis-
solving 25 mg drug in 3 mL of deionized water (inner 
water phase). The solution was sonicated for 30 seconds at 
20 W and then for 45 seconds at 35 W. The inner water phase 
was injected during sonication for one minute at 20 W in an 
organic phase which consisted of 250 mg of PLGA 504H 
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dissolved in 10 mL of dichloromethane. The resulting W/O 
emulsion was dispersed in 12.5 mL of the first outer water 
phase, a 0.5% w/v polyvinyl alcohol solution, and then soni-
cated for 30 seconds at 15 W to obtain a multiple W/O/W 
emulsion. The resulting emulsion was added to the second 
outer phase, consisting of 60 mL of 0.2% w/v polyvinyl 
alcohol in order to minimize coalescence of the emulsion. 
The organic solvent was allowed to evaporate during 4 hours 
at room temperature under gentle mixing. Finally, the nano-
particles were collected by centrifugation and freeze-dried 
after three times washing with deionized water.
S/O/W emulsion technique by ion pairing method
The synthesis scheme for PEGylated PLGA is shown in 
Figure 1. PEGylated PLGA was prepared according to the 
method developed by Esmaeili et al with a little modification.8 
Briefly, 2 g PLGA dissolved in dichloromethane was acti-
vated by dicyclohexylcarbodiimide (207 mg for PLGA 502H 
and 115 mg for 504H) and N-hydroxy succinimide (414 mg 
for PLGA 502H and 230 mg for 504H) at room temperature 
under a nitrogen atmosphere for 24 hours. The resulting 
mixture was filtered and precipitated by addition of ice-cold 
diethyl ether. The activated PLGA was dried under vacuum 
and then reacted with bis-amine PEG (200 mg for PLGA 
504H and 600 mg for 502H) in 16 mL of dichloromethane. 
Stoichiometric molar ratios of 1/1.5 and 1/1.1 were used for 
PLGA 504H/bis-amine PEG and PLGA 502H/bis-amine 
PEG, respectively. The reaction was performed for 6 hours 
under nitrogen atmosphere at room temperature. The result-
ing mixture was precipitated by dropping it into ice-cold 
diethyl ether. The precipitated PEGylated PLGA was filtered, 
dialyzed, and dried. H-NMR spectra for PEGylated PLGA 
were obtained using the Bruker Avence® 500 MHz, in CDCL3. 
(Figure 2). The conjugation percentage of terminal carboxylic 
acid of PLGA with bis-amine PEG was 100% (H-chemical 
shift –CH, –CH2, and –CH3 of PLGA and –CH2 of PEG are 
5.2, 4.8, 1.6, and 3.7 cm−1, respectively).
The method used for preparation of PEGylated PLGA 
nanoparticles was a combination of S/O/W and the ion 
pairing technique. We prepared four nanoparticle formula-
tions using two kinds of PLGA (502H and 504H) and 
dextran sulfate with two molecular weights (6000 and 
500,000). A 0.7 mL aqueous solution of minocycline HCl 
was injected into 10 mL of acetone solution containing 
200 mg PEGylated PLGA during sonication (40 W) for 
60 seconds. A 0.3 mL aqueous solution containing 24 mg 
dextran sulfate was added and sonicated for 30 seconds. 
The resulting solid in oil phase was added to 60 mL of 
continuous phase containing 0.5% polyvinyl alcohol as 
surfactant under homogenation (24,000 rpm for 5 minutes). 
The resulting nanoemulsion was maintained under gentle 
mixing for 3 hours. Consequently, the nanoparticles were 
collected by centrifugation and then freeze-dried after three 
times washing with deionized water.
Nanoprecipitation technique
Nanoprecipitation process was performed according to the 
method developed by Bilati et al, with a little modification.44 
PLGA 504H 50 mg and minocycline 20 mg were dissolved 
in 2 mL of dimethyl sulfoxide to form the diffusing phase. 
This phase was then injected to 10 mL of ethanol as a non-
solvent under gentle mixing. The resulting nanoparticles 
were then centrifuged three times for cycles of 20 minutes 
at 20,000 rpm and washed with deionized water.
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Figure 1 Synthesis of PEGylated-PLGA copolymer. 
Abbreviations: PEG, poly(ethylene) glycol; PLGA, poly(lactic-co-glycolic acid).
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Particle size and morphology 
characterization
Particle size and size distribution of the nanoparticles were 
investigated by laser light scattering (Malvern Zetasizer 
ZS, Malvern, Worcestershire, UK), after suspending 5 mg 
of the nanoparticles in 20 mL of deionized water. Three 
determinations were carried out for each formulation. 
Morphological characterization was conducted using scan-
ning electron microscopy (30XLFEG, Philips, Eindhoven, 
The Netherlands). Scanning electron microscopy was 
employed to determine the shape and surface morphology 
of the nanoparticles, and the particles were coated with gold 
using a sputter gold coater (BAL-TEC, Switzerland) under 
vacuum beforehand.
Differential scanning calorimetry
Differential scanning calorimetry (DSC) of minocycline, 
and empty and minocycline-loaded nanoparticles were 
performed on a Mettler DSC 823 (Mettler Toledo, 
S  witzerland) equipped with a Julabo Thermocryostate 
Model FT100Y (Julabolabortechnik GmbH, Germany). 
A Mettler Star software system, version 9.0× was used for 
data acquisition. DSC measurements were performed at a 
heating rate of 10°C/minute in the 20°C–350°C temperature 
range. The dry nanoparticles were weighed, put into an 
aluminum pan, and sealed carefully. During measurement, 
the sample cell was purged with nitrogen gas. Calibration 
of the instrument was performed.
Determination of drug loading  
and entrapment efficiency
The amount of minocycline entrapped in the nanoparticles 
was determined by HPLC analysis. The minocycline-loaded 
nanoparticles (20 mg) were dissolved in 5 mL acetonitrile 
and 10 mL of methanol was then added to precipitate the 
polymer. This procedure was performed using 10 mL of 
deionized water and 10 mL of dimethyl formamide for the 
minocycline-loaded nanoparticles. The samples were passed 
through a 0.22 µm Millipore membrane and the amount of 
drug was determined by HPLC analysis. The drug encapsula-
tion efficiency was determined from the mass ratio of the 
encapsulated drug to the amount of drug initially added. The 
amount of drug loading and encapsulation efficiency were 
calculated using the following equations:42
Drug loading (%) = (minocycline weight in sample/total 
weight of sample) × 100%
Encapsulation efficiency = (actual/theoretical   minocycline 
loading) × 100%
In vitro minocycline release  
from nanoparticles
Drug release from the nanoparticles was studied using a 
dialysis technique. A 20 mg sample of nanoparticles was 
resuspended in 5 mL of phosphate buffer solution at pH 7.4 
and placed in a dialysis bag (Spectra/Por®, molecular weight 
cutoff 2000 Da) sealed at both ends with clips (Spectra, 
  Torrance, CA). The dialysis bag was soaked in 40 L of phos-
phate buffer solution (pH 7.4) and maintained at 37°C ± 0.5°C 
and 100 ± 5 rpm shaking in a shaker (Heidolph Unimax 1010, 
Germany). At predetermined time intervals, individual 
samples were taken and the whole of the medium was replaced 
with 40 mL of fresh phosphate buffer solution. The amount 
of minocycline released into each medium was quantified by 
HPLC and compared with a standard calibration curve gener-
ated using known concentrations of minocycline.
The concentration of minocycline was analyzed using a 
modified USP HPLC method. HPLC analysis was performed 
at room temperature using a Knauer apparatus model K-1001, 
WellChrom (Berlin, Germany), equipped with a model PDA 
K-2700 ultraviolet detector (Knauer, Germany). The analytical 
column was Nucleodur® C18 (25 × 0.46 cm internal diameter, 
pore size 5 µm; Macherey-Nagel, Düren, Germany). The 
mobile phase consisted of 0.1 M ammonium oxalate, 0.005 
M edetate disodium, dimethyl formamide, and tetrahydrofuran 
(600:180:240:160 v/v) and adjusted with ammonium hydrox-
ide to a pH of 7.2. The flow rate was fixed at 1.5 mL per minute 
and ultraviolet detection was performed at 280 nm. The reten-
tion time of minocycline was about 7.46 ± 0.2 minutes. The 
concentration of minocycline was calculated for each sample 
using a calibration curve of known amounts of drug (with a 
linear regression coefficient of R = 0.999).
Antibacterial properties  
of minocycline-loaded nanoparticles
The antibacterial activity of the nanoparticles was compared 
with that of free minocycline by the well diffusion method 
using Aggregatibacter actinomycetocomitans (43718, 
American Tissue Culture Collection, Vanassus, VA). 
The surface of the brain heart infusion agar plates supple-
mented by hemin, vitamin K, bovine serum albumin, and 
sheep blood were seeded by the bacterial suspension at a 
cell density equivalent to 0.5 McFarland (1.5 × 108 CFU/mL). 
The antibacterial agent was sterilized by filtration using 
0.22 µm Millipore membranes. Wells with 8 mm diameters 
were prepared by punching a sterile cork borer onto the 
agar plates and removing the agar to form a well. Aliquots 
of 80 µL of each test compound solution (3.5 µg/mL 
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  minocycline powder in deionized water) were delivered 
into the wells. After 48 hours of incubation at 37°C, the 
inhibition zones around the wells were measured in 
  millimeters using a caliper.
The MIC and MBC of the test compounds were deter-
mined using the broth macrodilution method. A stock con-
centration of free drug was prepared in deionized water that 
was further diluted in brain heart infusion broth to reach a 
concentration range of 0.125 to 32 µg/mL. Based on the 
actual drug loading of the nanoparticles, the amount of 
nanoparticles in brain heart infusion broth was used to pro-
vide the equivalent concentration of minocycline similar to 
that of free drug. The final concentration of bacteria in the 
individual tubes was adjusted to about 5 × 105 CFU/mL. 
Control tubes contained PEGylated PLGA nanoparticles 
without drug and with no antibacterial agent. After 48 hours 
of incubation at 37°C, the test tubes were examined for pos-
sible bacterial turbidity, and the MIC of each test compound 
was determined as the lowest concentration that could inhibit 
visible bacterial growth. After MIC determination, an aliquot 
of 10 µL from all tubes in which no visible bacterial growth 
was observed was seeded in brain heart infusion agar plates 
not supplemented with any free minocycline or minocycline-
loaded nanoparticles. The plates were then incubated for 
48 hours at 37°C. The MBC endpoint is defined as the lowest 
concentration of antimicrobial agent that kills .99.9% of 
the initial bacterial population where no visible growth of 
the bacteria was observed on the plates.16,41
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Figure 2 h-Nuclear magnetic resonance spectrum of synthesized PEGylated PLGA in CDCL3. 
Abbreviations: PEG, poly(ethylene) glycol; PLGA, poly(lactic-co-glycolic acid).
Statistical analysis
Results were expressed as the mean ± standard deviation. 
One-way analyses of variance were performed for evaluation 
of the results. P values less than 0.05 were considered to be 
statistically significant.
Results
The basic characteristics of the minocycline-loaded nano-
particles prepared using various methods in this study are 
presented in Tables 1 and 2.
Particle size and morphology
All of the nanoparticles prepared from PLGA and PEG-
PLGA under various conditions had an acceptable size (less 
than 500 nm) and were suitable for our final clinical purposes 
except for the nanoparticles prepared using the oil in oil 
emulsion method (OO5). The mean particle sizes (z-average) 
of all the samples are shown in Table 1. The range of nano-
particle size was 85–7070 nm. It can be seen that the size of 
the nanoparticles was the smallest and largest when they 
were prepared using nanoprecipitation and the O/O emulsion 
method, respectively. A typical scanning electron micropho-
tograph of nanoparticles is shown in Figure 3. The 
  minocycline-PLGA nanoparticles were well defined and 
spherical, and had a smooth surface without pores. 
  Nanoparticles prepared by the nanoprecipitation method had 
the narrowest size distribution range with a polydispersity 
index of 0.08 (Figure 4A). Nanoparticles prepared by the 
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Table 1 Preparation of PLGA-based nanoparticles with different 
methods and their particle size
Sample Preparation method Mean 
diameter 
(nm)
OW1 Oil/water 193 ± 14
OW2 Modified  
oil/water
Lecithin in water 225 ± 23
OW3 Lecithin in oil 215 ± 16
OW4 Lecithin in two phases 242 ± 21
OO5 Oil/oil 7070 ± 208
WOW6 Water/oil/water 424 ± 17
SOW7 Solid/oil/water  
by ion pairing
PLGA (MW 48,000) +  
DS (MW 6000)
209 ± 19
SOW8 PLGA (MW 48,000) +  
DS (MW 500,000)
226 ± 15
SOW9 PLGA (MW 12,000) +  
DS (MW 6000)
139 ± 12
SOW10 PLGA (MW 12,000) +  
DS (MW 500,000)
186 ± 19
NPC11 Nanoprecipitation 85 ± 7
Abbreviations:  DS,  dextran  sulfate;  PLGA,  poly(lactic-co-glycolic  acid);  MW, 
molecular weight.
Table 2 Drug loading and entrapment efficiency
Sample Drug loading (%) ± SD Entrapment 
efficiency (%) ± SD
OW1 0.41 ± 0.02 3.85 ± 0.16
OW2 0.91 ± 0.03 4.14 ± 0.03
OW3 0.31 ± 0.01 1.48 ± 0.28
OW4 0.48 ± 0.02 2.15 ± 0.13
OO5 0.98 ± 0.04 5.48 ± 0.30
WOW6 0.44 ± 0.01 4.69 ± 0.21
SOW7 0.46 ± 0.015 7.69 ± 1.32
SOW8 0.78 ± 0.035 13.09 ± 2.40
SOW9 1.32 ± 0.12 22.23 ± 4.70
SOW10 1.92 ± 0.19 29.95 ± 2.47
NP11 0.26 ± 0.06 0.81 ± 0.18
Abbreviation: SD, standard deviation.
ACC V
17.0
Spot Magn Det WD 500 nm
kV 2.0 30,000xS E 9.5 SI
ACC V
17.0
Spot Magn Det WD 200 nm
kV 2.0 60,000xS E 9.6 SI
Figure 3 A typical scanning electron microphotograph of nanoparticles prepared by 
S/O/W ion pairing method, SOW10 (upper and lower image is presented at 30,000 
and 60,000× magnification, respectively).
S/O/W ion pairing method showed a somewhat good size 
distribution with a polydispersity index of 0.2 (Figure 4B).
Drug loading and entrapment efficiency
Table 2 displays the drug loading and entrapment efficiency 
for all the samples prepared using various methods. Drug 
loading ranged from 2.6 to 19.2 µg/mg. The least drug load-
ing (0.26%) and entrapment efficiency (0.81%) was found 
in nanoparticles prepared by the nanoprecipitation method. 
Significantly increased drug loading and entrapment effi-
ciency was obtained by the S/O/W ion pairing method (1.92% 
and 29.95%). Inclusion of dextran sulfate into the prepara-
tions (SOW7–10) significantly lowered the percentage of 
free minocycline compared with those without dextran sulfate 
(WOW6) and improved drug loading compared with other 
formulations. Nanoparticles prepared by the S/O/W ion pair-
ing method, with the highest entrapment efficiency, were 
used for other analyses.
DSC analysis
DSC thermograms of minocycline and the empty and 
  minocycline-loaded nanoparticles were obtained to define the 
physical state of the drug in the nanoparticles and thermal 
properties of the polymer nanoparticles. Figure 5 shows the 
DSC thermograms for minocycline, PLGA-PEG nanoparticles, 
and minocycline-PLGA-PEG nanoparticles (SOW10), 
  respectively. Pure minocycline showed an exothermic peak at 
200°C. There was no peak observed at this temperature for the 
nanoparticles. DSC studies did not detect any free minocycline 
in the nanoparticle samples. This confirmed the molecular 
dispersion of minocycline. After preparation the nanoparticles, 
minocycline could be in an amorphous phase of a molecular 
dispersion or in a solid solution state in the polymer matrix.
In vitro drug release
The in vitro release behavior of all nanoparticles is as 
  cumulative percentages in Figure 6. Release over 5 days 
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was measured. Release profiles for nanoparticles in   phosphate 
buffer solution (pH 7.4) were affected by the preparation 
methods and formulations used. The initial burst release was 
detected for all formulations during the first 7 hours (more 
than 20%) except for samples 1, 2, 5, and 6. The SOW9 
formulation showed a significantly higher burst release (72% 
in 7 hours) compared with the other formulations. The rate 
of drug release gradually decreased after about 1–2 days and 
remained constant even after 5 days (except for sample 9). 
As shown in Figure 6, drug release from the nanoparticles 
prepared by O/O was slower than from the other nanoparticles 
(approximately 10% in 5 days).
Antibacterial properties of minocycline 
nanoparticles
The minocycline-loaded nanoparticles, free minocycline, and 
empty nanoparticles were tested against Aggregatibacter 
actinomycetemcomitans in vitro to compare their antibacterial 
activity. In the case of minocycline-loaded PLGA-PEG nano-
particles, the SOW10 sample had the highest entrapment 
efficiency. A well diffusion assay showed that the inhibition 
zone of minocycline-loaded nanoparticles (9.2 mm) was greater 
than that of free minocycline (3.5 mm) and empty PLGA 
nanoparticles, which did not show any inhibitory effect. The 
MICs of the samples are shown in Table 3. The MIC of 
minocycline-loaded nanoparticles (4 µg/mL) was two-fold less 
than for free minocycline (8 µg/mL). The MBC of minocycline-
loaded nanoparticles (8 µg/mL) was also two-fold less than 
that for free minocycline (16 µg/mL). Therefore, it can be seen 
that the antibacterial activity of minocycline-loaded nanopar-
ticles was greater than for the free drug. Empty nanoparticles 
diluted with brain heart infusion broth as a control did not show 
any antibacterial effect against the bacteria tested. Hence it can 
be concluded that there was no antibacterial interaction between 
PLGA and the tested bacteria.
Discussion
The choice of a suitable nanoparticle preparation method is 
dependent on the physicochemical properties of the drug to 
be encapsulated. Different methods have been successfully 
used  for  the  entrapment  of  lipophilic  drugs  into 
nanoparticles.33,45 The main problem in the preparation of 
minocycline-loaded nanoparticles was the lack of drug 
  loading and entrapment efficiency because minocycline is a 
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Figure 4 Particle size distributions of nanoparticles prepared by (A) S/O/W ion pairing method (SOW10) and (B) nanoprecipitation method (NP11).
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Figure 5 DSC thermograms of minocycline, PLGA-PEG, and minocycline-PLGA-PEG nanoparticles. 
Abbreviations: DSC, differential scanning calorimetry; PEG, poly(ethylene) glycol; PLGA, poly(lactic-co-glycolic acid).
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Table  3  MIC  and  MBC  of  free  drug  and  minocycline-loaded 
nanoparticles  against  Aggregatibacter  actinomycetemcomitans  by 
macrodilution method
Free drug (μg/mL) Minocycline-loaded 
nanoparticles (μg/mL)
MIC 8 4
MBC 16 8
Abbreviations: MIC, minimum inhibitory concentration; MBC, minimum bacterial 
concentration.
hydrophilic compound and there is a concern about increasing 
the drug loading of hydrophilic agents.35 However, in prac-
tice, preparation of nanoparticles with the desired properties 
(adequate entrapment efficiency and drug loading, suitable 
release profile, and particle size distribution) can be difficult 
due to the large number of factors influencing the outcome 
of nanoparticle preparation. In this study, several experiments 
were carried out to determine the best method and the formula 
with the highest antibiotic loading of PLGA nanoparticles.
Nanoparticles prepared by solvent diffusion methods 
(OW1 and WOW6) showed low entrapment efficiency and 
drug loading because minocycline rapidly diffused from the 
hydrophobic matrix into the external aqueous phase during 
preparation.46 Compared with the solvent diffusion method, 
better entrapment efficiency and drug loading were obtained 
by the O/O emulsion evaporation method (OO5). This was 
contributed to by the liquid paraffin used as a continuation 
phase with this method.42 The limited solubility of minocy-
cline and nil diffusion of first oil into liquid paraffin were 
advantageous to restrict minocycline leakage in comparison 
with other aqueous solvent diffusion methods. Polymeric 
particles obtained by this method had the largest particle size. 
An increase of particle size with the O/O method might have 
been due to the high viscosity of the continuous phase which 
hinders the homogenous dispersion of polymer solution into 
the continuous phase. Particle size is key to the biological 
fate of nanoparticle carriers. Decreasing size improves the 
permeation and penetration of nanoparticle carriers.   Therefore, 
nanoparticles should have an appropriate size to penetrate 
the bacterial cell wall. Inclusion of lecithin into the aqueous 
phase (OW2) using the O/W method led to improvement in 
entrapment efficiency and drug loading compared with the 
standard method (OW1). In this regard, adding lecithin has 
been shown to result in surface adsorption of amphiphilic 
lecithin onto nanoparticles through hydrophobic   interactions.36 
Minocycline interacts with the hydrophobic phospholipid 
tails of lecithin similar to lecithin-PLGA interactions. 
  Incorporating lecithin onto the nanoparticle surface can 
enhance entrapment efficiency by trapping minocycline in 
the   phospholipid layer. However, inclusion of lecithin in the 
oil phase (OW3) and both phases (oil and water) (OW4) had 
the reverse effect on entrapment efficiency and drug loading. 
Lecithin adsorption onto the nanoparticle surface caused a 
minor increase in particle size (about 10%–20%).
Nanoparticles prepared by the nanoprecipitation method 
were considerably smaller (80 ± 7 nm) than nanoparticles 
prepared by the emulsion method. The size distribution of 
nanoparticles prepared using this method is shown in 
  Figure 4A, where a highly uniform size distribution is 
observed (polydispersity index 0.08). Briefly, there are two 
miscible solvents when using this method. Drug and polymer 
dissolve in the first one as the solvent. Nanoprecipitation 
occurs by rapid diffusion and a precipitate of the polymer 
when the first polymer solution is added to the second phase 
as a nonsolvent.44 Precipitation involves immediate drug 
entrapment. Nanoparticles prepared by this method show the 
lowest drug loading and entrapment efficiency compared 
with the other methods (Table 2). Because rapid diffusion 
of drug-polymer solution into the second phase increased the 
amount of free drug in the second phase, this method was 
unable to retain substantial amounts of minocycline to incor-
porate into the polymer matrix.
High entrapment efficiency using the S/O/W ion pairing 
method occurred as follows. This method was a combination 
of S/O/W emulsion and ion pairing techniques (Figure 7). 
An aqueous solution of minocycline was added to an organic 
solution of PEGylated PLGA. Addition of aqueous dextran 
sulfate solution produced a minocycline-dextran sulfate 
precipitate (solid in oil). Dextran sulfate was used as an ion 
pairing agent to reduce drug solubility by coacervation. The 
resulting solid in the oil phase was then added to the aqueous 
polyvinyl alcohol solution. The organic solvent was removed 
by evaporation under stirring to produce nanoparticles. The 
electrostatic forces formed between opposite ions, cationic 
minocycline and anionic dextran sulfate, and cationic PEGy-
lated PLGA and anionic dextran sulfate. Dextran sulfate as 
an ion pairing agent played a role as an ionic spacer between 
PEGylated PLGA and minocycline. If ion pairing formation 
is faster than polymer precipitation, the ion pairs could be 
trapped during particulate precipitation. In the absence of 
dextran sulfate (WOW6), the interactions between the ter-
minal group of the polymer and minocycline were mostly 
directed by weak van der Waal’s forces. According to the 
H-NMR results, the PEG content in low molecular weight 
PLGA (502H, molecular weight 12,000) was approximately 
four times more than the high molecular weight PLGA 
(504H, molecular weight 48,000). So a high amount of ion 
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pairs was formed in low molecular weight PEGylated 
PLGA, and hence drug entrapment was increased (SOW9 
and SOW10).
The significantly increased entrapment efficiency and 
drug loading using high molecular weight dextran sulfate 
(500,000) indicates that the additional negative charges of 
dextran sulfate have further incorporated minocycline (about 
2.3–2.9 times). This was due to an ion pairing mechanism 
which was mentioned earlier. Improved interaction between 
the drug and polymer and thus entrapment efficiency was 
obtained by increasing PEGylation and a high molecular 
weight of dextran sulfate.
The size of the nanoparticles prepared by different double 
emulsion methods was as follows: WOW6 (424 nm) . SOW7 
(209 nm) . SOW9 (139 nm). The reduction in particle size 
could be largely due to the decrease in PLGA molecular 
weight (SOW9) and increase in amphiphilic properties of 
the polymer with increasing PEG content (SOW7 and 9). 
These polymers with higher PEG content reduce interfacial 
tension to facilitate nanoparticle formation, and result in a 
smaller particle size.47 An approximately narrow size 
  distribution was also observed (Figure 4B) for the nanopar-
ticles prepared by S/O/W method (polydispersity index 0.2).
The release kinetics of minocycline from the nanoparticles 
was ideal, as usually an initial burst release in the first 24 hours 
followed by a controlled pattern of drug release is clinically 
favorable.25,48,49 In most of the nanoparticles prepared in this 
work (OO5, WOW6, SOW7–9, NP10), we observed linear 
  minocycline release rates after the burst effect for more than 
5 days, and this profile could be ideal for periodontal disease.50 
The initial burst could be ascribed to the minocycline distrib-
uted at or just beneath the surface of the   nanoparticles. The 
later constant release is mainly due to drug diffusion and 
matrix erosion mechanisms. The minocycline release 
rate from nanoparticles in 24 hours was as follows:
•	 OW1 (18%) . WOW6 (14%) . OO5 (6%). From the 
sustained drug release of OO5, it can be assumed that 
minocycline was well dispersed in the polymer matrix, 
which allowed regular release of minocycline with poly-
mer degradation. The large size of the particles 
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Figure 7 Scheme of combination of S/O/W emulsion and ion pairing techniques.
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(OO5 . WOW6 . OW1) decreased the solid-liquid 
contact and drug diffusion through the polymeric wall.
•	 OW3 (59%) . OW4 (49%) . OW1 (18%) . OW2 
(14%). The effect of lecithin on the release rate was 
similar to its effect on entrapment efficiency. In sample 
OW2 entrapment efficiency was improved and the release 
rate was reduced. Conversely, in samples OW3 and OW4 
entrapment efficiency was decreased and the release rate 
was enhanced.
•	 SOW9  (91%)  .  SOW10  (72%),  and  SOW7 
(38%) . SOW8 (29%). Nanoparticles prepared using 
dextran sulfate (molecular weight 500,000) showed a 
slower release rate than dextran sulfate alone (molecular 
weight 6000). This may be due to a higher negative charge 
related to dextran sulfate 500,000 that induced better 
interaction with the cationic drug and which could incor-
porate further amounts of drug on the inside as well as 
the surface of the nanoparticles.
•	 SOW10  (72%)  .  SOW8  (29%),  and  SOW9 
(91%) . SOW7 (38%). Use of low molecular weight 
PLGA in SOW9 and SOW10 increased the diffusion of 
minocycline through the nanoparticle wall.51 Nanopar-
ticles with the highest PEG content have more amphiphilic 
and hydrophilic properties. These properties enhance 
molecular diffusion into aqueous solution.
•	 SOW7 (38%) . WOW3 (14%). As mentioned earlier, 
nanoparticles prepared by the S/O/W ion pair method 
have more amphiphilic and hydrophilic properties and 
smaller particle size. These properties enhance diffusion 
and surface desorption in aqueous solution.
Thermal studies were used to investigate the physical 
state of minocycline in the nanoparticles, because this prop-
erty could influence drug release from the nanoparticles. 
Drug may be present either as amorphous or crystalline in 
an amorphous or crystalline polymer. Figure 3 shows the 
DSC thermograms for pure minocycline, and for empty and 
minocycline-loaded nanoparticles. Polymer shows a glass 
transition temperature at 50°C and does not have a melting 
point temperature, meaning that it is an amorphous polymer. 
Two peaks in the temperature range of 150°C–170°C may 
be related to residence of polyvinyl alcohol. Pure minocycline 
showed an exothermic peak at 200°C related to the melting 
point with decomposition transition. Minocycline melting 
with a decomposition peak was depleted in the thermogram 
for the loaded nanoparticles, indicating the presence of 
amorphous minocycline in the nanoparticles. It may be 
hypothesized that crystallization of minocycline is inhibited 
during production of nanoparticles. Therefore, minocycline 
in the nanoparticles is in the amorphous phase of a molecular 
dispersion. The antibacterial properties of minocycline-
loaded nanoparticles were determined in vitro; the antibacte-
rial activity of the nanoparticles was remarkable and mainly 
attributed to the high antibacterial effect of the nanosized 
particles (Table 3). Encapsulation of minocycline into 
nanoparticles improved the antibacterial efficiency of 
minocycline against standard Aggregatibacter actinomy-
cetemcomitans by two-fold. Because free drug and nano-
particles were investigated using the same concentration 
of minocycline, the improvement in antibacterial effect 
activity be due to better penetration of the nanoparticles 
into bacterial cells and better delivery of minocycline to its 
site of action.7 Nanoparticles are capable of being endocy-
tosed by phagocytic cells and releasing drug into those 
cells.52,53 The minocycline-loaded nanoparticles could be 
suitable for delivery of minocycline to phagocytic cells to 
achieve better treatment of infection compared with treat-
ment using free minocycline. This indicates that the newly 
designed antibiotic-releasing nanoparticles may be appro-
priate for periodontal treatment.
Conclusion
Effective entrapment of drugs that are highly soluble in both 
aqueous and organic solvents is difficult to achieve using 
standard approaches, such as single and double emulsification 
solvent evaporation and nanoprecipitation methods. In this 
study we used a novel method for the preparation of mino-
cycline-loaded nanoparticles by applying an ion pairing 
technique using solid/oil/water emulsification. Our results 
demonstrate that using PLGA-PEG-dextran sulfate for ion 
pairing significantly increases minocycline loading, and 
produces nanoparticles with the desired size, size distribution, 
and morphological properties. By decreasing the molecular 
weight of PLGA and increasing the molecular weight of 
dextran sulfate, the desired drug content can be obtained 
because of the high PEG content and low drug insolubility, 
respectively. PEGylated PLGA (molecular weight 12,000) 
and dextran sulfate (molecular weight 500,000) was the 
preferred choice for ion pairing because it allowed the highest 
drug loading and entrapment efficiency. An investigation of 
different preparation methods, physicochemical characteriza-
tion, in vitro release testing, and antibacterial properties of 
the nanoparticles was carried out. Release rates varied 
depending on the preparation method and nanoparticle char-
acteristics, such as amphiphilic, polymer molecular weight, 
particle size, and polymer composition. In vitro release 
indicated that after the initial burst release, controlled release 
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of minocycline continued for more than 5 days; this release 
profile could be the ideal for periodontal disease.   Nanoparticles 
prepared by nanoprecipitation had a good size and 
  morphology; however, this is not an efficient method for 
  encapsulation of highly water-soluble drugs such as mino-
cycline (reverse of nanoparticles prepared by oil/oil method). 
The in vitro antibacterial results showed that the minocycline-
loaded nanoparticles are remarkably more effective than the 
free drug against Aggregatibacter actinomycetemcomitans.
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